A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects

Trial Profile

A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs MEDI 0700 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 25 Jul 2017 Planned number of patients changed from 40 to 48.
    • 25 Jul 2017 Planned End Date changed from 1 Aug 2017 to 26 Oct 2017.
    • 25 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 26 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top